

Ref. No: 2538
Date: 27th April 2026
Subject: Transthyretin amyloidosis (ATTR) Referrals

REQUEST and RESPONSE

For the most recent three complete calendar years (e.g. 2023, 2024 and 2025), please provide:

1. The number of patients your Trust referred onwards with a suspected or confirmed diagnosis of transthyretin amyloidosis (ATTR).

<5 patients

If possible, please break this down by:

Year

Referring specialty (e.g. cardiology, neurology, nephrology)

<5 by Urology in 2023

<5 by Haematology in 2024

2. For the same period, please specify:
The external centre(s) to which patients with suspected or confirmed ATTR amyloidosis were referred (e.g. National Amyloidosis Centre, regional amyloidosis hubs, tertiary cardiology centres).

National Amyloidosis Centre

3. Where available, please include:
The number of patients referred to each centre per year.

<5 to National Amyloidosis Centre 2023

<5 to National Amyloidosis Centre 2024

Note that the information was searched using the ICD-10 Code: E85.8 - Other amyloidosis and (discharged between 01/01/2023 and 31/12/2025), in the absence of a dedicated ICD-10 code for the Transthyretin amyloidosis condition.

